Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

By Zelnak Amelia B.   Wisinski Kari B.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 17-24

Blackwell Publishing

Access to resources Recommend Favorite

Trastuzumab: In HER2-Positive Metastatic Gastric Cancer

By Croxtall Jamie D.   McKeage Kate  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2259-2267

Adis International

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

By Murthy Rashmi K.   Varma Ankur   Mishra Priyankana   Hess Kenneth R.   Young Elliana   Murray James L.   Koenig Kimberly H.   Moulder Stacy L.   Melhem-Bertrandt Amal   Giordano Sharon H.   Booser Daniel   Valero Vicente   Hortobagyi Gabriel N.   Esteva Francisco J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

Blackwell Publishing

Access to resources Recommend Favorite

Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years

By Kawai Masaaki   Malone Kathleen E.   Tang Mei-Tzu C.   Li Christopher I.  

Cancer, Vol. 120, Iss. 10, 2014-05 ,pp. : 1548-1556

Blackwell Publishing

Access to resources Recommend Favorite